Skip to main content
Clinical Trials/NCT00876278
NCT00876278WithdrawnPhase 4

Prospective Clinical Study to Evaluate Usability of Mesotest II for Assessment of Night Driving Capacity of Pseudophakic Patients Implanted With Monofocal IOL *AT.Smart 46LC

Carl Zeiss Meditec AG2 sites in 1 countryStarted: June 2009Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Withdrawn
Locations
2
Primary Endpoint
Measurement of contrast sensitivity and sensitivity to light under mesopic conditions (Mesotest II, Oculus).

Study Overview

Brief Summary

Pilot study to evaluate usability of Mesotest II for assessment of night driving capacity of pseudo-phakic patients implanted with aspheric monofocal posterior chamber IOL *AT.Smart 46LC.

Target Criterion:

Measurement of contrast sensitivity and sensitivity to light under mesopic conditions (Mesotest II, Oculus).

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Masking
None

Eligibility Criteria

Ages
50 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Healthy eyes with cataract
  • Patient age 50-75 years
  • Written Patient Informed Consent
  • Assured follow-up examination

Exclusion Criteria

  • Any kind of macula degeneration and impairment of retina (clinical diagnosis)
  • Amblyopia
  • Intraoperative complications; damaged posterior bag; intraocular haemorrhage
  • Astigmatism > 1.5 D (objective, preoperative)
  • Pregnancy or lactation period for female patients

Outcomes

Primary Outcomes

Measurement of contrast sensitivity and sensitivity to light under mesopic conditions (Mesotest II, Oculus).

Time Frame: 8 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials